Florida’s surprise primary result, with democratic socialist Angie Nixon advancing in the Senate race, has pushed healthcare policy risk back into the spotlight. For investors, the stakes around Medicare, Medicaid and ACA funding now feel more tangible. This can quickly reprice expectations for U.S. Healthcare and Managed Care stocks. This article walks through three stocks exposed to that shifting policy debate and explains why each might matter for your portfolio watchlist.

The stocks covered below are just a starting sample. The full screen surfaced 36 more U.S. Healthcare and Managed Care companies with equally compelling policy and quality narratives that are not discussed here. To identify and analyze those additional ideas, head straight to the U.S. Healthcare and Managed Care Stocks screener.

Oscar Health (OSCR)

Oscar Health is a U.S. healthcare technology insurer that focuses on ACA exchange and individual health plans, which ties it closely to the Medicare, Medicaid and ACA-linked theme of this screener. The company generates about US$15.32b in insurance revenue from life and health products in the United States, supported by digital tools such as its +Oscar and Campaign Builder platforms for payors, providers and brokers. At a market cap of roughly US$9.73b, Oscar Health is a mid cap player with scale and clear exposure to policy and subsidy trends.

Oscar Health gives you direct exposure to the ACA and individual insurance story at a time when policy risk is front of mind after Florida’s upset primary result. The company has recently turned profitable and is linking that profit profile to technology driven platforms, new marketplaces like Lucie Health for retail drugs, and employer focused offerings such as ICHRAx. That mix of regulated revenue and tech enabled distribution can be powerful, but it comes with real watchpoints, including heavy use of external funding, past dilution and meaningful insider selling. If you want a case study in how policy shifts could reprice a fast growing, government linked insurer, Oscar Health is hard to ignore.

Oscar Health’s shift to profitability with tech driven insurance platforms and government linked revenue raises a sharp question. Are investors correctly pricing that mix of growth and policy risk, or missing a key twist highlighted in the 3 key rewards and 2 important warning signs

Build your own Oscar Health style policy risk shortlist

Oscar Health and the other two stocks in this article all come from a single screener, but the real edge is setting your own filters around policy exposure, profitability and balance sheet strength. Use our flexible Screener to shape ideas that fit your style, or tap into pre-built themes with our Investing Ideas.

Humana (HUM)

Humana is one of the largest U.S. Medicare Advantage and government backed health plan insurers, which ties it closely to policy discussions around Medicare and Medicaid. Most of its roughly US$139.7b in revenue comes from the Insurance segment that offers Medicare Advantage, prescription drug plans, military health services and specialty coverage, while the CenterWell segment adds about US$24.7b from senior focused primary care, home health and pharmacy services. The entire US$145.8b revenue base is generated in the United States, and the company has a market cap of about US$46.1b.

Humana provides direct exposure to any policy push toward wider public coverage, with Medicare Advantage, Medicaid and military health contracts deeply embedded in its Insurance and CenterWell businesses. The company is working on margin recovery through AI driven efficiency, Stars score improvement and selective exits from less profitable Medicare Advantage plans, while also expanding Medicaid and home health services. At the same time, earnings remain sensitive to reimbursement formulas, one off losses and heavy use of external borrowing, so any change in Washington or misstep on medical costs can affect results quickly.

Humana’s push to reset margins and refocus on stronger Medicare and Medicaid lines is only half the picture. The real story is in how those moves reshape risk and opportunity in the 2 key rewards and 2 important warning signs

Centene (CNC)

Centene is a pure-play U.S. managed care company that connects directly to the Medicare, Medicaid and ACA theme by running government-sponsored health plans for under-insured and uninsured Americans. Most of its roughly US$180.3b in revenue comes from Medicaid at about US$92.6b, with US$40.4b from Medicare, US$40.7b from Commercial marketplace and group products, and around US$5.0b from other services such as pharmacy, vision, dental and behavioral health. The entire revenue base is generated in the United States, and Centene has a market cap of about US$31.8b.

Centene gives investors a focused way to express a view on public healthcare spending at a time when the Florida primary result has put Medicare and Medicaid policy back in play. The company is working on Medicaid margin recovery, improving Medicare Advantage economics and sharpening ACA marketplace pricing. It still carries execution risk related to medical costs, specialty drugs and future reimbursement decisions. Analysts have highlighted both upside potential and policy-related downside. Centene is a policy-sensitive stock where getting the details right on contracts, margins and capital allocation could make a significant difference to outcomes over the next few years.

Centene’s government backed growth story is tightly linked to policy, yet the real swing factor may be hiding in the 3 key rewards and 1 important warning sign

Seeking Fresh Alternatives Beyond Healthcare?

New themes can start breaking out while attention stays locked on policy headlines. Use these fresh stock shortlists before they are caught by the crowd and consider them while they are still underfollowed.

• Target resilient cash generators that may hold up when momentum shifts by running a curated list of solid balance sheet and fundamentals (50 results) and spot which businesses still fly under the radar for now.
• Focus on structural demand in core materials by scanning the hand picked 9 top copper producer stocks and see which producers could gain traction if sentiment turns back toward real assets.
• Track rising automation trends before they go mainstream with a focused 37 robotics and automation stocks and identify which companies are quietly building momentum while it still matters.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.